A study to evaluate the safety and tolerability and to assess blood levels of seltorexant in adolescents with Major Depressive Disorder who have not responded well to their current antidepressant and psychotherapy - Trial 2021-000567-77
Access comprehensive clinical trial information for 2021-000567-77 through Pure Global AI's free database. This phase not specified trial is sponsored by Janssen-Cilag International NV and is currently status unknown. The study focuses on Major Depressive Disorder.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to EU Clinical Trials Register data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Free Database
Powered by Pure Global AI
840K+ Trials
2021-000567-77
Trial Details
EU Clinical Trials Register • 2021-000567-77
A study to evaluate the safety and tolerability and to assess blood levels of seltorexant in adolescents with Major Depressive Disorder who have not responded well to their current antidepressant and psychotherapy
Study Focus
Sponsor & Location
Janssen-Cilag International NV
Timeline & Enrollment
N/A
N/A
N/A
Primary Outcome
Any potential participant who meets any of the following criteria will be excluded from participating in the study:
ICD-10 Classifications
Recurrent depressive disorder
Recurrent depressive disorder, unspecified
Depressive conduct disorder
Other recurrent depressive disorders
Recurrent depressive disorder, current episode moderate
Data Source
EU Clinical Trials Register
2021-000567-77
Non-Device Trial